Biophysics

Bestqool Introduces Revolutionary Red Light Therapy for Home-Based Yogis: A New Horizon in Wellness and Yoga Practice

Retrieved on: 
Friday, March 22, 2024
Well, AIMS, Glass, Yoga, COVID-19, Education, Link, Tissue, Research, Muscle fatigue, Joint, Student, Aesthetic Surgery Journal, Woman, Integrative Cancer Therapies, Patient satisfaction, Safety, Human factors and ergonomics, Red light, Martin, Biophysics, Health care

Well, the solution is simple - use Red Light Therapy alongside and make the most of your fitness experience in a more streamlined, healthier way.

Key Points: 
  • Well, the solution is simple - use Red Light Therapy alongside and make the most of your fitness experience in a more streamlined, healthier way.
  • It is recommended that all home-based yogis and yoga practitioners incorporate the use of Red Light Therapy at three stages of their lives, that is before, during, and after their yoga sessions.
  • Furthermore, Red Light therapy would work as a much-needed companion for your yoga sessions.
  • Bestqool 's hand-held Red Light Therapy devices are designed with the user in mind, offering ease of use, safety, and efficiency.

A-GAME Announces Appointment of Thomas Bond, MD, MS as Chief Medical Officer

Retrieved on: 
Thursday, March 21, 2024
Doctor of Medicine, Health, Longevity, Bond, Drink, Intervention, Nutrition, Regenerative medicine, Physician, Education, Patient, Family medicine, University, Athlete, Exercise, Biophysics, Carolinas Medical Center, Sports medicine, Major League Baseball, LSU, Dentistry

ORLANDO, Fla., March 21, 2024 (GLOBE NEWSWIRE) -- A-GAME Beverages Inc. (“A-GAME”), creator of the “ultimate” hydration beverage, is pleased to announce the appointment of Dr. Thomas Bond as Chief Medical Officer.

Key Points: 
  • ORLANDO, Fla., March 21, 2024 (GLOBE NEWSWIRE) -- A-GAME Beverages Inc. (“A-GAME”), creator of the “ultimate” hydration beverage, is pleased to announce the appointment of Dr. Thomas Bond as Chief Medical Officer.
  • Bond will act as the first Chief Medical Officer for A-GAME Beverages and bring years and valuable experience of both clinical and sideline expertise in the field of Sports Medicine.
  • Dr.
  • Bond was recruited to LSU Medical Center in New Orleans as the Chief of Sports Medicine.

FundaMental Pharma Appoints Industry Veteran Dr. Lorenz Mayr as Non-Executive Director

Retrieved on: 
Wednesday, March 20, 2024
Medicines Discovery Catapult, Francis Crick Institute, AstraZeneca, Science, Drug discovery, Novartis, Fraunhofer, Patient, IPA, University, GE HealthCare, Biophysics, Fundamental, Investment, Pharmaceutical industry

Lorenz is a highly respected biopharmaceutical executive with extensive experience over the last 30 years in drug discovery, technology and innovation, business growth and financing strategy.

Key Points: 
  • Lorenz is a highly respected biopharmaceutical executive with extensive experience over the last 30 years in drug discovery, technology and innovation, business growth and financing strategy.
  • Lorenz has extensive global experience in pharmaceutical R&D, including positions as Vice President & Global Head at AstraZeneca and Executive Director at Novartis and Bayer Pharmaceuticals.
  • Keno Gutierrez, Chairman of the Board of FundaMental Pharma, commented: “We are excited to share that Lorenz, a seasoned and highly regarded industry leader, has joined our Board of Directors.
  • I am confident that Lorenz`s energy, conceptual guidance and reach will make a difference in advancing FundaMental Pharma`s key program to the next level.”

Conformation-X Therapeutics Bolts out of Stealth, Securing Over $13.5M in Funding to Propel Its Innovative Immune-Oncology Pipeline

Retrieved on: 
Wednesday, April 3, 2024
Research, Venture Capital, Professional Services, Biotechnology, Health, Pharmaceutical, Other Science, Science, Oncology, TME, IL18BP, Patient, Neoplasm, Tumor microenvironment, Biology, Biophysics, Therapy, Cancer, Structural biology, Escape Room

Drawing inspiration from the fundamental role of protein conformations in disease biology and drug efficacy, Conformation-X applies unparalleled precision to developing novel immune checkpoint inhibitors.

Key Points: 
  • Drawing inspiration from the fundamental role of protein conformations in disease biology and drug efficacy, Conformation-X applies unparalleled precision to developing novel immune checkpoint inhibitors.
  • The company is creating a comprehensive portfolio of differentiated therapeutics addressing cancer mechanisms that have eluded existing treatments.
  • Dr. Munawar added, “We are committed to pioneering alternative therapeutic options for these patients by targeting novel biology and molecular pathways.
  • Our work highlights the strength of Conformation-X’s drug discovery platform,” said Dr. Stephen Weeks, Sr. Director of Structural Biology and Biophysics.

Atomwise Publishes Results from 318-Target Study Showcasing AtomNet AI Platform’s Ability to Discover Structurally Novel Chemical Matter

Retrieved on: 
Tuesday, April 2, 2024
Research, Technology, Neurology, Health Technology, Biotechnology, Managed Care, Pharmaceutical, Health, Science, Artificial Intelligence, AIMS, Biochemistry, Disease, Executive, University, HTS, Patient, AI, Scientific Reports, OTUD7B, IND, PPM1D, Biology, Biophysics, Cancer, Pharmacokinetics, TYK2, Development, Probability, Artificial intelligence, Proteome, Pharmaceutical industry

Atomwise announced today results from the AIMS (Artificial Intelligence Molecular Screen) initiative that establish the AtomNet AI Platform as a viable alternative to high-throughput screening (HTS) and verify its ability to consistently discover structurally novel chemical matter.

Key Points: 
  • Atomwise announced today results from the AIMS (Artificial Intelligence Molecular Screen) initiative that establish the AtomNet AI Platform as a viable alternative to high-throughput screening (HTS) and verify its ability to consistently discover structurally novel chemical matter.
  • AtomNet also showed a remarkable ability to discover novel chemical matter, averaging over seven structurally distinct bioactive compounds per target.
  • Developed by Atomwise, AtomNet was the first deep neural network designed to predict the bioactivity of small molecules in structure-based drug discovery.
  • Our belief is structurally novel chemical matter increases the likelihood of developing first-in-class and best-in-class medicines that have the potential to transform patient care.

Playground Global Promotes Benjamin Kim PhD to Partner

Retrieved on: 
Wednesday, February 28, 2024
Biotechnology, Technology, Professional Services, Health, Pharmaceutical, Research, Software, Genetics, Science, Hardware, Finance, Therapy, Doctor of Philosophy, Multimedia, AI, Principal, Immunotherapy, Investment, General partnership, Growth, Playground Global, Stanford University, National Science Foundation, Protein engineering, Biophysics, Lead, Venture, Ecosystem, Automation, Biomedical engineering, Playground, College of Engineering (KNUST), Biology, Fine chemical

Playground Global , an early-stage, deep-tech venture firm that invests in founders building category-defining businesses at the forefront of science and technology, today announced that Benjamin Kim PhD, has been promoted to Partner.

Key Points: 
  • Playground Global , an early-stage, deep-tech venture firm that invests in founders building category-defining businesses at the forefront of science and technology, today announced that Benjamin Kim PhD, has been promoted to Partner.
  • View the full release here: https://www.businesswire.com/news/home/20240228985705/en/
    Ben joined Playground as a Venture Fellow in 2019 while completing his PhD in bioengineering at Stanford University.
  • “It’s an honor to contribute to the Playground life sciences ecosystem and support our portfolio companies in evolving deeply technical breakthroughs into transformational businesses,” said Ben Kim, PhD, Partner at Playground.
  • “Ben brings an infectious passion for and incredible knowledge of bioengineering and biophysics to the Playground team,” said Jory Bell , General Partner at Playground.

The Inner Circle Acknowledges, Bohdan Minczak as a Pinnacle Lifetime Member

Retrieved on: 
Wednesday, March 6, 2024
Love, Saint Joseph's College, Jefferson Health, College, Doctor of Philosophy, Inner circle, Medicine, Education, MD, Emergency medicine, Physician, Temple University, Master, Biophysics, Bachelor, Mentorship, Pharmacology, Thomas Jefferson University, Associate, Patient, Family, ABEM, Knowledge, Research, Thomas Jefferson, Nursing

CHELTENHAM, Pa., March 6, 2024 /PRNewswire/ -- Prominently featured in The Inner Circle, Bohdan Minczak is acknowledged as a Pinnacle Lifetime Member for his contributions to the Medical field.

Key Points: 
  • CHELTENHAM, Pa., March 6, 2024 /PRNewswire/ -- Prominently featured in The Inner Circle, Bohdan Minczak is acknowledged as a Pinnacle Lifetime Member for his contributions to the Medical field.
  • Dr. Bohdan Minczak is a distinguished emergency medicine physician with a rich background in healthcare, research, and academia.
  • Dr. Minczak is a renowned specialist in the realm of emergency medicine, with a deep understanding of physiology and biophysics.
  • His multifaceted expertise extends to public speaking and lecturing, enabling him to effectively communicate complex medical concepts to diverse audiences.

Molecular Assemblies Announces the Appointment of Two Industry Leaders to Its Commercial-Technology Advisory Board

Retrieved on: 
Tuesday, February 13, 2024
Therapy, Sigma-Aldrich, Epigenomics, Cornell University, MAI, Bruker, Abraxis BioScience, Principal, Biotechnology, Research, General partnership, Viridos (company), NGS, St. Louis, Biophysics, Protein engineering, Doctor of Philosophy, Gen-Probe, Synthetic biology, Gene editing, Cell biology, Dicarboxylic acid, Gene, Oligonucleotide, Thermo Fisher Scientific, Genomics, Horizon Discovery, CTAB, DNA, Fine chemical

"With the deep knowledge, wisdom, and experience commercializing transformative life science products, the CTAB enables Molecular Assemblies to identify emerging opportunities and trends in the life sciences industry that can be solved with our breakthrough nucleic acid-based products," said Larry Stambaugh, Board Chair of Molecular Assemblies.

Key Points: 
  • "With the deep knowledge, wisdom, and experience commercializing transformative life science products, the CTAB enables Molecular Assemblies to identify emerging opportunities and trends in the life sciences industry that can be solved with our breakthrough nucleic acid-based products," said Larry Stambaugh, Board Chair of Molecular Assemblies.
  • "Molecular Assemblies is helping accelerate the life science industry by removing one of the largest bottlenecks in R&D – the availability of long, pure, accurate oligonucleotides," said Todd C. Peterson, Ph.D., CTAB Chair and MAI Board Director.
  • He is currently Founder and Principal at GenApex Bio, a life sciences Board service and advisory practice.
  • His extensive experience includes leadership roles at Sigma-Aldrich and Genome Systems, where he made significant contributions to the genomics field.

Seer Proteograph™ Enables Unprecedented Genetic Marker Mapping for Proteogenomics Studies to Advance Drug and Biomarker Discovery

Retrieved on: 
Tuesday, February 6, 2024
Marker beacon, Manuscript, Bioinformatics, Peptide, Weill Cornell Medicine, Research, Genetic variation, Nature Communications, Cardiovascular disease, Gene, Nanoparticle, Proteome, Metabolomics, GIP, Drug discovery, Mass spectrometry, Protein, Medicine, Biophysics, Proteomics, Physiology, Plasma

REDWOOD CITY, Calif., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (NASDAQ: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced a publication in Nature Communications from a study led by Weill Cornell Medicine showing Seer’s Proteograph workflow to potentially unveil novel proteogenomic insights into genetics-based drug and biomarker discovery for precision medicines. Designed to address the challenges with affinity-based proteomic approaches for protein quantitative trait loci (pQTL) studies, the scalable, high-resolution Proteograph workflow enables scientists to link genetic variation with protein abundance with peptide level resolution.

Key Points: 
  • The study found 184 PAVs in 137 genes, confirmed by their variant peptides in mass spectrometry data, known as MS-PAV.
  • Most MS-PAVs were aligned with known genetic markers (cis-pQTLs), validating the target specificity of the method.
  • Seer's approach provides customers with unparalleled insights into drug response analysis, drug discovery, patient stratifications for clinical studies, and precision medicine.
  • “At Seer, we offer researchers a new method for pQTL mapping and a deeper understanding of proteins and peptides for large-scale proteogenomic studies.”

Ultima Genomics Announces End of Early Access and Upcoming Launch of UG 100™

Retrieved on: 
Tuesday, January 30, 2024
Biotechnology, Pharmaceutical, Medical Supplies, Oncology, Health, Medical Devices, Health Technology, Genetics, Partnership, Whole genome sequencing, Genomics, Liquid biopsy, Workflow, Gold, Research, DNA, Access, Science, Environment, Patient, Exact sciences, Diagnosis, CLIA, Broad Institute, Laboratory, Chemistry, Harvard University, Drug discovery, Automation, Weill Cornell Medicine, Disease, Biophysics, Silicon, Biology, MIT, Physiology, Doctor of Philosophy, Medicine, Cancer, Genome, Early access, SNV

The UG 100™ is an ultra-high throughput system purposefully built for high-volume applications.

Key Points: 
  • The UG 100™ is an ultra-high throughput system purposefully built for high-volume applications.
  • “After much anticipation, we are excited to publicly announce the full commercial availability of the $100 genome at the upcoming AGBT conference in February,” said Gilad Almogy, Founder and CEO of Ultima.
  • We are excited to be an early adopter of Ultima’s technology and the first to have the instrument installed in the Asia-Pacific region.
  • Ultima will be introducing the UG 100™ and will be providing additional information about its ppmSeq™ technology on February 6th at the AGBT conference as part of its Gold Sponsorship plenary presentation.